Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Marc Gitzinger | M | - |
BioVersys AG
 BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland. | 16 jaar |
| William John Jenkins | M | 77 |
BioVersys AG
BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland. | - |
| Seng Chin Mah | M | - |
BioVersys AG
BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland. | - |
| Daniel O.A. Rüedi | M | - |
BioVersys AG
BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland. | - |
| David Hunstad | M | - |
BioVersys AG
BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Zwitserland | 5 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Marina von Schönau
- Persoonlijk netwerk
